Technology Transfer

Transforming Our Discoveries Into Therapeutics

The Technology Transfer Office embodies the spirit of the National Jewish Health brand promise, Science Transforming Life^®. We accelerate the development of basic scientific research toward clinical application by identifying and protecting the institution's intellectual property and facilitating business partnerships for technology development, licensing, and commercialization.

National Jewish Health currently has in its portfolio:

• 116 active technologies developed from our research

• 86 active U.S. patents protecting these technologies

• 50 percent of those active US patents are licensed to biotechnology companies for the development of therapeutics consistent with the spirit of the National Jewish Health brand promise, Science Transforming Life.

Additionally, in the 20 years since the Technology Transfer Office was created, National Jewish Health has:

• executed 279 license agreements, of which 139 are still active;

• executed a total of 2341 material transfer agreements; and

• helped create 11 start-up companies.

Technologies from National Jewish Health

To browse a list of the technologies ready for licensing or further development, select one of the following:

• Therapeutics
   
• Diagnostics
   
• Research Tools: Antibodies, Cell Lines, Animal Models & Transgenic Mice

• Biomedical Devices
   
• Start-Up Companies created with National Jewish Health technologies

Featured Technology: Novel TLR Inhibitors Prevent Respiratory Syncytial Virus Infection In Vivo